CCMINC
CRL icon

Cardinal Capital Management Inc (North Carolina)’s Charles River Laboratories CRL Stock Holding History

Cardinal Capital Management Inc (North Carolina)’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Buy
11,206
+175
+2% +$31.2K 0.31% 91
2026
Q1 		$1.9M Buy
11,031
+103
+0.9% +$19.1K 0.25% 103
2025
Q4 		$2.18M Buy
10,928
+62
+0.6% +$11.2K 0.29% 97
2025
Q3 		$1.7M Sell
10,866
-4
-0% -$635 0.24% 107
2025
Q2 		$1.65M Buy
10,870
+147
+1% +$19.6K 0.24% 106
2025
Q1 		$1.61M Buy
10,723
+223
+2% +$37.4K 0.25% 105
2024
Q4 		$1.94M Sell
10,500
-4
-0% -$771 0.3% 94
2024
Q3 		$2.07M Buy
10,504
+312
+3% +$64.8K 0.32% 88
2024
Q2 		$2.11M Buy
10,192
+370
+4% +$83.8K 0.35% 85
2024
Q1 		$2.66M Buy
9,822
+1,372
+16% +$328K 0.43% 75
2023
Q4 		$2M Buy
8,450
+47
+0.6% +$9.24K 0.38% 81
2023
Q3 		$1.65M Buy
8,403
+178
+2% +$36.5K 0.34% 85
2023
Q2 		$1.73M Buy
8,225
+83
+1% +$16.5K 0.35% 85
2023
Q1 		$1.64M Buy
8,142
+73
+0.9% +$16.5K 0.34% 89
2022
Q4 		$1.76M Buy
8,069
+156
+2% +$34.1K 0.37% 81
2022
Q3 		$1.56M Buy
7,913
+196
+3% +$42.3K 0.37% 80
2022
Q2 		$1.65M Buy
7,717
+53
+0.7% +$13K 0.38% 77
2022
Q1 		$2.18M Buy
7,664
+159
+2% +$49K 0.44% 71
2021
Q4 		$2.83M Sell
7,505
-56
-0.7% -$21.8K 0.56% 63
2021
Q3 		$3.12M Buy
7,561
+8
+0.1% +$3.32K 0.68% 55
2021
Q2 		$2.79M Sell
7,553
-78
-1% -$26K 0.59% 60
2021
Q1 		$2.21M Buy
7,631
+36
+0.5% +$10K 0.49% 69
2020
Q4 		$1.9M Buy
7,595
+64
+0.8% +$15.2K 0.45% 73
2020
Q3 		$1.71M Buy
7,531
+154
+2% +$32K 0.47% 64
2020
Q2 		$1.29M Buy
7,377
+267
+4% +$42.6K 0.37% 76
2020
Q1 		$897K Sell
7,110
-881
-11% -$132K 0.3% 86
2019
Q4 		$1.22M Sell
7,991
-129
-2% -$17.9K 0.32% 89
2019
Q3 		$1.07M Sell
8,120
-115
-1% -$15.4K 0.3% 88
2019
Q2 		$1.17M Sell
8,235
-203
-2% -$27.5K 0.33% 87
2019
Q1 		$1.23M Sell
8,438
-21
-0.2% -$2.76K 0.35% 83
2018
Q4 		$957K Buy
8,459
+137
+2% +$17.2K 0.32% 83
2018
Q3 		$1.12M Buy
8,322
+27
+0.3% +$3.33K 0.32% 89
2018
Q2 		$931K Buy
8,295
+42
+0.5% +$4.54K 0.28% 96
2018
Q1 		$880K Sell
8,253
-82
-1% -$8.84K 0.28% 94
2017
Q4 		$912K Sell
8,335
-112
-1% -$12.2K 0.28% 91
2017
Q3 		$912K Buy
8,447
+549
+7% +$56.4K 0.29% 91
2017
Q2 		$799K Buy
7,898
+863
+12% +$79.4K 0.26% 92
2017
Q1 		$633K Buy
7,035
+76
+1% +$6.46K 0.23% 93
2016
Q4 		$530K Buy
6,959
+900
+15% +$68.4K 0.2% 99
2016
Q3 		$505K Buy
6,059
+422
+7% +$35.4K 0.2% 95
2016
Q2 		$465K Buy
5,637
+259
+5% +$21.3K 0.19% 98
2016
Q1 		$408K Buy
5,378
+341
+7% +$25.2K 0.17% 99
2015
Q4 		$405K Buy
5,037
+175
+4% +$12.6K 0.18% 96
2015
Q3 		$309K Buy
4,862
+515
+12% +$37K 0.14% 102
2015
Q2 		$306K Buy
4,347
+671
+18% +$49.7K 0.13% 106
2015
Q1 		$291K Buy
3,676
+496
+16% +$36.6K 0.12% 103
2014
Q4 		$202K Buy
+3,180
New +$199K 0.09% 110

Other funds holding CRL

CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Cardinal Capital Management Inc (North Carolina)'s CRL Position: Q2 2026 in Review

Cardinal Capital Management Inc (North Carolina) increased its Charles River Laboratories (CRL) stake by 1.6% in Q2 2026, buying an estimated $31.2K and bringing the position to 11,206 shares worth $2.54M. The position accounts for 0.31% of the portfolio, ranked #91.

Cardinal Capital Management Inc (North Carolina) first reported a position in CRL in Q4 2014 and has held it in 47 quarters since. The position peaked at $3.12M in Q3 2021. 178 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Cardinal Capital Management Inc (North Carolina) held 11,206 shares of Charles River Laboratories worth $2.54M as of Q2 2026.
  • Cardinal Capital Management Inc (North Carolina) bought 175 Charles River Laboratories shares in Q2 2026, an estimated $31.2K.
  • Charles River Laboratories made up 0.31% of Cardinal Capital Management Inc (North Carolina)'s portfolio in Q2 2026, its #91 holding.
  • Cardinal Capital Management Inc (North Carolina) first reported a position in Charles River Laboratories in Q4 2014 and has held it in 47 quarters since.
  • Cardinal Capital Management Inc (North Carolina)'s Charles River Laboratories position peaked at $3.12M in Q3 2021.
  • 178 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Cardinal Capital Management Inc (North Carolina)'s 13F filing for Q2 2026, filed 21 Jul 2026.